1. Home
  2. ELVN vs AAT Comparison

ELVN vs AAT Comparison

Compare ELVN & AAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • AAT
  • Stock Information
  • Founded
  • ELVN 2016
  • AAT 1967
  • Country
  • ELVN United States
  • AAT United States
  • Employees
  • ELVN N/A
  • AAT N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • AAT Real Estate Investment Trusts
  • Sector
  • ELVN Health Care
  • AAT Real Estate
  • Exchange
  • ELVN Nasdaq
  • AAT Nasdaq
  • Market Cap
  • ELVN 1.1B
  • AAT 1.2B
  • IPO Year
  • ELVN 2020
  • AAT 2011
  • Fundamental
  • Price
  • ELVN $16.53
  • AAT $19.05
  • Analyst Decision
  • ELVN Strong Buy
  • AAT Hold
  • Analyst Count
  • ELVN 4
  • AAT 2
  • Target Price
  • ELVN $39.25
  • AAT $23.00
  • AVG Volume (30 Days)
  • ELVN 359.8K
  • AAT 514.4K
  • Earning Date
  • ELVN 05-13-2025
  • AAT 04-29-2025
  • Dividend Yield
  • ELVN N/A
  • AAT 7.14%
  • EPS Growth
  • ELVN N/A
  • AAT 12.42
  • EPS
  • ELVN N/A
  • AAT 0.94
  • Revenue
  • ELVN N/A
  • AAT $453,339,000.00
  • Revenue This Year
  • ELVN N/A
  • AAT $4.44
  • Revenue Next Year
  • ELVN N/A
  • AAT $1.87
  • P/E Ratio
  • ELVN N/A
  • AAT $20.24
  • Revenue Growth
  • ELVN N/A
  • AAT 3.79
  • 52 Week Low
  • ELVN $13.30
  • AAT $16.69
  • 52 Week High
  • ELVN $30.03
  • AAT $29.15
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 40.34
  • AAT 44.61
  • Support Level
  • ELVN $15.49
  • AAT $18.75
  • Resistance Level
  • ELVN $18.14
  • AAT $18.65
  • Average True Range (ATR)
  • ELVN 1.93
  • AAT 0.80
  • MACD
  • ELVN -0.17
  • AAT 0.10
  • Stochastic Oscillator
  • ELVN 41.09
  • AAT 62.77

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About AAT American Assets Trust Inc.

American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.

Share on Social Networks: